Amgen Plans Phase III Program for Next-Gen Obesity Drug Targeting Liver and Kidney Diseases

cafead

Administrator
Staff member
  • cafead   Sep 05, 2024 at 11:52: AM
via A broad indication for MariTide could help Amgen secure Medicare coverage for the treatment following FDA approval, CEO Robert Bradway said at Wednesday’s Morgan Stanley Global Healthcare Conference.

article source